Sidewinder Therapeutics develops next-generation precision Antibody-Drug Conjugate (ADC) therapeutics. The company focuses on creating innovative medicines that target specific molecular drivers of disease. Their goal is to deliver new life-saving therapies for patients suffering from cancer and rare diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer and rare disease treatments often lack the precision needed to target specific molecular drivers, leading to suboptimal patient outcomes and potential off-target effects. There is a need for therapies that can selectively address the unique biological mechanisms underlying these conditions.
Solution
Sidewinder Therapeutics is developing a new generation of large molecule precision biologics designed to target specific molecular drivers in cancer and rare diseases. Their approach focuses on creating tailored treatment options that can improve patient outcomes by addressing the unique biological mechanisms of these conditions. By targeting highly specific molecular drivers, Sidewinder aims to deliver life-saving therapies with improved precision and reduced off-target effects. The company is advancing innovative medicines through a dynamic team of experienced entrepreneurs, scientists, and drug developers.
Target Audience
The primary target audience includes patients with cancer and rare diseases, as well as healthcare providers seeking more precise and effective treatment options.
Features
- Development of large molecule precision therapeutics.
- Therapies target specific molecular drivers of cancer and rare diseases.
- Focus on creating tailored treatment options.